Champions Oncology, Inc. - Company Summary

Business Overview

Champions Oncology, Inc. is a technology-enabled research organization focused on drug discovery and development in the oncology (cancer) field. The company develops and utilizes advanced platforms combining computational biology, biomarker analysis, and experimental research to facilitate more rapid, precise, and cost-effective cancer drug research.

Core Technology Platforms

• TumorGraft Technology Platform:

  • A bank of approximately 1,500 Patient Derived Xenograft (PDX) models. These models involve implanting human tumors in immune-deficient mice, allowing for detailed biological and molecular characterization.
  • The models reflect characteristics of patients in clinical trials, especially those with late-stage, pretreated, and metastatic cancers.
  • These models are highly characterized at molecular, phenotypic, and pharmacological levels.

• Datacenter:

  • Contains extensive data: about 3,500 molecular datasets (genomics, transcriptomics, proteomics), roughly 3,000 clinical drug responses, and about 3,500 in vivo drug responses, alongside clinical patient data.
  • Includes additional publicly available datasets (~20,000) for genomic and functional studies.
  • Data is derived from a living TumorBank, allowing ongoing characterization and expansion.

• Software as a Service (SaaS):

  • Lumin Bioinformatics: A proprietary platform combining the Datacenter's data with analytics and artificial intelligence tools.
  • Provides insights on biomarker hypotheses, mechanisms of therapeutic resistance, and guides preclinical studies.

Business Lines

1. Research Services:

   • Performs preclinical in vivo studies (implanting tumors in mice) to evaluate the efficacy of oncology drugs.
   • Includes bioinformatics analyses to identify genetic signatures associated with drug responses, resistance, or sensitivity.
   • Clients are pharmaceutical and biotech companies.
   • Revenue primarily from custom in vivo studies; typical study costs range from $125,000 to $500,000.
   • Since 2019, growth rate of ~12% annually, with around 500 clients over ten years, including repeat customers across North America, Europe, and Asia.
   • Revenue for FY ending April 30, 2025: $56.9 million (up 14% from $50.2 million in FY 2024).

2. Data Licensing:

   • Offers access to proprietary PDX model data via licensing agreements.
   • Data includes genomic and pharmacologic information useful for drug discovery.

3. SaaS Platform - Lumin:

   • Subscriptions sold on an annual basis.
   • Utilized by cancer researchers to analyze the company's large oncology dataset.
   • Helps develop biomarker hypotheses, understand mechanisms of resistance, and plan further research.

4. Drug Discovery and Development:

   • Leverages the Datacenter, AI, and experimental platforms for identifying and validating novel oncology therapeutic targets.
   • Focus areas include targeted therapies with drug conjugates, immuno-oncology, and cell therapies.
   • Pipelines are at various discovery and validation stages, with some progressing to therapeutics.
   • Business strategy explores additional value creation via spin-outs or capital raises.
   • Utilizes a dedicated team of computational and experimental scientists.
   • Revenue impact from this segment is not explicitly provided but under active development.

Financial Highlights

• Revenue (FY ending April 30, 2025): $56.9 million
• Net Income (FY ending April 30, 2025): $4.7 million (profit)
• Revenue (FY ending April 30, 2024): $50.2 million
• Net Loss (FY ending April 30, 2024): $7.3 million
• Number of Employees: approximately 213 full-time employees (as of July 15, 2025)
  • 93 hold doctoral or advanced degrees
  • 159 are involved in R&D
  • 32 in sales & marketing
  • 22 in finance & administrative roles

Additional Information

• The company operates primarily in the United States and Europe, with a subsidiary in Israel and Italy.
• The company has approximately 1,900 stockholders as of July 2025.
• No current litigation or legal proceedings.
• The company cooperates with over 500 pharmaceutical and biotech clients over ten years, with significant repeat business.
• The company emphasizes cutting-edge, proprietary platforms aimed at revolutionizing oncology research and drug development.

Note: This summary is based strictly on the provided document and reflects the company's current business model, assets, revenues, and personnel as of the fiscal year ending April 30, 2025.